by Admin | Mar 14, 2026 | Safety Signals
EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has completed its review of a safety signal involving aseptic meningitis with Ixchiq, the live attenuated chikungunya vaccine. EMA said PRAC has recommended an update to the product information to reflect the...
by Admin | Mar 13, 2026 | Safety Signals
In February 2026, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) concluded its safety review of levamisole-containing medicines and recommended that their marketing authorisations be withdrawn from the EU market. EMA said the review...
by Admin | Mar 13, 2026 | Safety Signals
The Pan American Health Organization has called for strengthened pharmacovigilance following reports of misuse involving GLP-1 medicines indicated for treating obesity in adults. PAHO published the warning on 3 March 2026, placing additional public-health and...